Greenstone Biosciences, Inc. Announces Collaboration with the Maryland Stem Cell Research Fund to Provide Curated Induced Pluripotent Stem Cell Lines to Stem Cell Investigators Across the State of Maryland

The stem cell lines provided through this collaboration empower Maryland stem cell scientists to advance their research toward cures.

Palo Alto, CA, Aug 23, 2022 – Greenstone Biosciences, Inc. (“Greenstone Bio”), a commercial stage computational biology company, announces today that the Company has entered into a collaboration with the Maryland Stem Cell Research Fund (“MSCRF”) to provide, at no cost, human induced Pluripotent Stem Cell (iPSC) lines to investigators at academic universities and other research institutions who conduct human stem cell research in the State of Maryland.

Greenstone Bio (Stanford Research Park) focuses on clinical genomics, iPSC technology, AI/ML, and drug development. The company has established extensive knowledge and expertise in generating patient-derived human iPSCs and differentiation into numerous cell types for disease modeling and drug discovery.

Established in 2006 by the Governor and the Maryland General Assembly through the Maryland Stem Cell Research Act, MSCRF’s goal is to accelerate stem cell-based research, commercialization, and cures by providing funding and resources to public and private entities in the State of Maryland. 

Dr. Joseph Wu, Greenstone Bio co-founder said, “This is a great collaboration that translates Greenstone Bio’s expertise in iPSC technology to accelerate therapies to improve patient care – fast-tracking bench to bedside.” Dr. Wu is the Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine & Radiology at Stanford University. Greenstone Board Chairman Lip-Bu Tan of Walden Catalyst Venture is a long-term strategic partner.  Mr. Tan considers “this a wonderful and strategic translational medicine partnership with the Maryland Stem Cell Research Fund.”

Dr. Amritha Jaishankar, MSCRF’s Executive Director said, “We are delighted to collaborate with Dr. Joseph Wu and Greenstone Bio to make this valuable resource available to our faculty at research institutions across the State of Maryland. I’m confident that this open-source innovation and collaboration model will advance the stem cell field, and that our concerted efforts will accelerate research and therapies for diverse patients with unmet medical needs in the near term.”

About Greenstone Biosciences, Inc.

Greenstone Bio is a commercial stage computational biology company specializing in stem cell technology, artificial intelligence & machine learning, and drug discovery. For further information about the Company, please visit www.greenstonebio.com.

Greenstone Biosciences, Inc. Contact

Jade Chao

Chief Operating Officer

Greenstone Biosciences, Inc. jadechao@greenstonebio.com

About The Maryland Stem Cell Research Fund (MSCRF)

MSCRF is focused on identifying and fostering cutting-edge research and innovation in the field of regenerative medicine in the State of Maryland. MSCRF’s Accelerating Cures initiative comprises programs that help transition human stem cell-based technologies from the bench to the bedside, as well as mechanisms to build and grow stem cell companies in Maryland. MSCRF is committed to accelerating stem cell research, cures, and commercialization, in addition to building a collaborative stem cell community. For further information about MSCRF’s mission and funding opportunities, please visit www.mscrf.org.

Maryland Stem Cell Research Fund (MSCRF) Contact

Dr. Amritha Jaishankar

Executive Director

The Maryland Stem Cell Research Fund

ajaishankar@tedco.md

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.    

Read original article